Last Price$233.1(0.2%)
Market Cap$34.6B
12.9%
Peers median - 2.5%
28.2%
Peers median - 9.7%
16.0%
Peers median - 29.8%
32.9%
Peers median - 7.5%
Competing with RMD
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$34.6B | 7.6 | $190.6 18.2% overvalued | 29.9% | $4,926.8M | $1,388.4M | 12.9% | 28.2% | 57.9% | 32.9% | 16.0% | |
$207.3B | 6.9 | $106.1 81.3% overvalued | 41.5% | $8,352.1M | $1,077.2M | 17.2% | 12.9% | 67.5% | 26.8% | 0.0% | |
$66.3B | 6.1 | $262.7 15.0% undervalued | (1.4%) | $20.6B | $2,936.0M | 5.9% | 14.2% | 59.4% | 5.4% | 55.9% | |
$46.6B | 6.4 | $81.3 13.6% overvalued | 9.9% | $9,926.1M | $608.0M | 3.6% | 6.1% | 55.6% | 9.1% | 23.8% | |
$18.6B | 5.8 | $92.7 1.2% undervalued | (10.8%) | $3,895.4M | $288.1M | 8.4% | 7.4% | 62.8% | 5.9% | 32.0% | |
$17.9B | 4.7 | $52.7 51.1% undervalued | (16.2%) | $12.9B | $566.0M | (14.0%) | 4.4% | 37.1% | (1.5%) | 191.5% | |
$16.9B | 6.1 | $152.8 33.0% overvalued | (36.3%) | $2,893.1M | $276.4M | (1.9%) | 9.6% | 34.6% | 18.6% | 11.3% | |
$14.7B | 7.3 | $131.7 108.2% undervalued | (15.2%) | $4,038.9M | $1,135.5M | 1.8% | 28.1% | 56.2% | 13.2% | 1.0% | |
$10.4B | 5.2 | $139.9 26.6% overvalued | 50.3% | $2,094.4M | $145.3M | 2.3% | 6.9% | 48.0% | (14.8%) | 69.2% | |
$9,757.8M | 6.5 | $174.5 19.0% undervalued | 4.2% | $3,582.9M | $349.2M | 2.7% | 9.7% | 48.7% | 12.0% | 27.7% | |
$8,979.7M | 5.9 | $29.8 80.8% overvalued | (20.6%) | $616.0M | $131.3M | (8.0%) | 21.3% | 46.9% | (1.2%) | 33.3% |
Compare RMD Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
ResMed Inc.RMD
7.1x
10.9%
13.4%
21.8%
Median Peer Set
5.1x
1.7%
23.0%
10.2%
Alcon Inc.ALC
5.0x
8.5%
182.9%
10.3%
AptarGroup, Inc.ATR
2.9x
2.7%
30.2%
10.5%
Baxter International Inc.BAX
2.3x
(69.5%)
(100.0%)
(6.9%)
Becton, Dickinson and CompanyBDX
4.1x
4.2%
18.3%
8.4%
The Cooper Companies, Inc.COO
5.4x
8.4%
32.2%
10.1%
Hologic, Inc.HOLX
3.2x
(0.0%)
81.1%
19.6%
Intuitive Surgical, Inc.ISRG
24.3x
17.2%
27.7%
27.8%
Masimo CorporationMASI
5.2x
0.6%
(42.5%)
4.0%
Repligen CorporationRGEN
14.4x
(21.1%)
(80.9%)
5.6%
West Pharmaceutical Services, Inc.WST
5.8x
(1.9%)
(15.5%)
17.0%
Compare RMD Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does ResMed Inc. (RMD) revenue growth compare to peers and the industry?
ResMed Inc. (RMD) revenue growth is 12.9%, compared to the peers' median of 2.5%.
2. How does ResMed Inc. (RMD) Free Cash Flow (FCF) margin compare to peers and the industry?
ResMed Inc. (RMD) FCF margin is 28.2%, compared to the peers' median of 9.7%.
3. How does ResMed Inc. (RMD) Total Debt to Equity ratio compare to peers and the industry?
ResMed Inc. (RMD) Total Debt to Equity ratio is 16.0%, compared to the peers' median of 29.8%.
4. How does ResMed Inc. (RMD) ROIC (Return on Invested Capital) compare to peers and the industry?
ResMed Inc. (RMD) ROIC is 32.9%, compared to the peers' median of 7.5%.